ACUR · As filed with the SEC
Acura Pharmaceuticals income statement, by quarter
The statement as Acura Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS · USD, except per-share amounts
| USD, except per-share amounts | Q4 2021 3 months ended Dec 31, 2021 | Q3 2021 3 months ended Sep 30, 2021 | Q2 2021 3 months ended Jun 30, 2021 | Q1 2021 3 months ended Mar 31, 2021 | Q4 2020 3 months ended Dec 31, 2020 | Q3 2020 3 months ended Sep 30, 2020 | Q2 2020 3 months ended Jun 30, 2020 | Q1 2020 3 months ended Mar 31, 2020 |
|---|---|---|---|---|---|---|---|---|
| Revenues: | ||||||||
| Royalties | — | 67,000 | 3,000 | 32,000 | — | 14,000 | 34,000 | 33,000 |
| Collaboration from related party | — | 3,000 | 10,000 | 12,000 | — | 96,000 | 44,000 | 8,000 |
| License fees from related party | — | 200,000 | 600,000 | 600,000 | — | 300,000 | 1,050,000 | 1,050,000 |
| Product sales | — | 0 | 0 | — | — | 0 | 223,000 | — |
| Total revenues | — | 270,000 | 613,000 | 644,000 | — | 410,000 | 1,351,000 | 1,091,000 |
| Expenses: | ||||||||
| Research and development | — | 385,000 | 390,000 | 405,000 | — | 519,000 | 445,000 | 387,000 |
| General and administrative | — | 416,000 | 523,000 | 385,000 | — | 456,000 | 485,000 | 1,187,000 |
| Total expenses | — | 801,000 | 913,000 | 790,000 | — | 975,000 | 930,000 | 1,574,000 |
| Operating loss | — | (531,000) | (300,000) | (146,000) | — | (565,000) | 421,000 | (483,000) |
| Loss on debt extinguishment (Note 7) | — | — | — | — | — | 0 | 0 | — |
| Interest expense - related party (Note 9) | — | — | (87,000) | — | — | — | — | — |
| Gain on forgiveness of a loan under CARES Act | — | 269,000 | — | — | — | — | — | — |
| Interest expense to related party | — | 0 | — | (113,000) | — | (113,000) | (113,000) | (112,000) |
| Loss before provision for income taxes | — | (262,000) | (387,000) | (259,000) | — | (678,000) | 308,000 | (595,000) |
| Provision for income taxes | — | 0 | 0 | 0 | — | 0 | 0 | 0 |
| Net loss | — | (262,000) | (387,000) | (259,000) | — | (678,000) | 308,000 | (595,000) |
| Net income (loss) per share: | ||||||||
| Basic | — | 0.00 | (0.01) | (0.01) | — | (0.02) | 0.01 | (0.02) |
| Diluted | — | 0.00 | (0.01) | (0.01) | — | (0.02) | 0.01 | (0.02) |
| Weighted average number of shares outstanding: | ||||||||
| Basic | — | 75,561,000 | 42,889,000 | 32,464 | — | 32,336,000 | 32,304,000 | 32,270,000 |
| Diluted | — | 75,561,000 | 42,889,000 | 32,464 | — | 32,336,000 | 32,482,000 | 32,270,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.